RT Journal Article
SR Electronic
T1 Large scale phenotyping of long COVID inflammation reveals mechanistic subtypes of disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.06.07.23291077
DO 10.1101/2023.06.07.23291077
A1 Liew, Felicity
A1 Efstathiou, Claudia
A1 Fontanella, Sara
A1 Richardson, Matthew
A1 Saunders, Ruth
A1 Swieboda, Dawid
A1 Sidhu, Jasmin K.
A1 Ascough, Stephanie
A1 Moore, Shona C.
A1 Mohamed, Noura
A1 Nunag, Jose
A1 King, Clara
A1 Leavy, Olivia C.
A1 Elneima, Omer
A1 McAuley, Hamish J.C.
A1 Shikotra, Aarti
A1 Singapuri, Amisha
A1 Sereno, Marco
A1 Harris, Victoria C
A1 Houchen-Wolloff, Linzy
A1 Greening, Neil J
A1 Lone, Nazir I
A1 Thorpe, Matthew
A1 Roger Thompson, A. A.
A1 Rowland-Jones, Sarah L.
A1 Docherty, Annemarie B.
A1 Chalmers, James D.
A1 Ho, Ling-Pei
A1 Horsley, Alexander
A1 Raman, Betty
A1 Poinasamy, Krisnah
A1 Marks, Michael
A1 Kon, Onn Min
A1 Howard, Luke
A1 Wootton, Daniel G.
A1 Quint, Jennifer K.
A1 de Silva, Thushan I.
A1 Ho, Antonia
A1 Chiu, Christopher
A1 Harrison, Ewen M
A1 Greenhalf, William
A1 Kenneth Baillie, J.
A1 Semple, Malcolm G.
A1 Evans, Rachael A.
A1 Wain, Louise V.
A1 Brightling, Christopher
A1 Turtle, Lance
A1 Thwaites, Ryan S.
A1 Openshaw, Peter J.M.
A1 ,
YR 2023
UL http://medrxiv.org/content/early/2023/06/12/2023.06.07.23291077.abstract
AB One in ten SARS-CoV-2 infections result in prolonged symptoms termed ‘long COVID’, yet disease phenotypes and mechanisms are poorly understood. We studied the blood proteome of 719 adults, grouped by long COVID symptoms. Elevated markers of monocytic inflammation and complement activation were associated with increased likelihood of all symptoms. Elevated IL1R2, MATN2 and COLEC12 associated with cardiorespiratory symptoms, fatigue, and anxiety/depression, while elevated MATN2 and DPP10 associated with gastrointestinal (GI) symptoms, and elevated C1QA was associated with cognitive impairment (the proteome of those with cognitive impairment and GI symptoms being most distinct). Markers of neuroinflammation distinguished cognitive impairment whilst elevated SCG3, indicative of brain-gut axis disturbance, distinguished those with GI symptoms. Women had a higher incidence of long COVID and higher inflammatory markers. Symptoms did not associate with respiratory inflammation or persistent virus in sputum. Thus, persistent inflammation is evident in long COVID, distinct profiles being associated with specific symptoms.Competing Interest StatementFL, CE, DS, JKS, SCM, CD, CK, NM, LN, EMH, ABD, JKQ, LPH, KP, LH, OMK, SF, TIdS, DGW, RST and JKB have no conflicts of interest. AART receives speaker fees and support to attend meetings from Janssen Pharmaceuticals. SLRJ is on the data safety monitoring board for Bexero trial in HIV+ adults in Kenya. JDC is the deputy chief editor of ERS and receives consulting fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Insmed, Janssen, Novartis, Pfizer and Zambon. AH is Deputy chair of NIHR Translational Research Collaboration (unpaid role). BR receives honoraria from Axcella therapeutics. RAE is co-lead of PHOSP-COVID and receives fees from Astrazenaca / Evidera for consultancy on Long Covid and from Astrazenaca for consultancy on digital health. RAE has received speaker fees from Boehringer in June 2021 and has held a role as European Respiratory Society Assembly 01.02 Pulmonary Rehabilitation secretary. RAE is on the American Thoracic Society Pulmonary Rehabilitation Assembly programme committee. LVW also receives funding from Orion pharma and GSK and holds contracts with Genentech and AstraZenaca. LVW has received consulting fees from Galapagos and Boehringer, is on the data advisory board for Galapagos and is Associate Editor for European Respiratory Journal. AH is a member of NIHR Urgent Public Health Group (June 2020-March 2021). MM is an applicant on the PHOSP study funded by NIHR/DHSC. MGS acts as an independent external and non-remunerated member of Pfizers External Data Monitoring Committee for their mRNA vaccine program(s), is Chair of Infectious Disease Scientific Advisory Board of Integrum Scientific LLC, Greensboro, NC, USA and is director of MedEx Solutions Ltd and majority owner of MedEx Solutions Ltd and minority owner of Integrum Scientific LLC, Greensboro, NC, USA. MGS has been in receipt of gifts from Chiesi Farmaceutici S.p.A. of Clinical Trial Investigational Medicinal Product without encumbrance and distribution of same to trial sites. MGS is a non-renumerated member of HMG UK New Emerging Respiratory Virus Threats Advisory Group (NERVTAG) and has previously been a non-renumerated member of SAGE. CB has received consulting fees and/or grants from GSK, AZ, Genentech, Roche, Novartis, Sanofi, Regeneron, Chiesi, Mologic and 4DPharma. LT has received consulting fees from MHRA and speak fees from Eisai Ltd. LT has a patent pending with ZikaVac. PJMO reports grants from the EU Innovative Medicines Initiative (IMI) 2 Joint Undertaking during the submitted work; grants from UK Medical Research Council, GlaxoSmithKline, Wellcome Trust, EU-IMI, UK, National Institute for Health Research, and UK Research and Innovation-Department for Business, Energy and Industrial Strategy; and personal fees from Pfizer, Janssen, and Seqirus, outside the submitted work.Clinical Protocols https://phosp.org/resource/ Funding StatementThis research used data assets made available by Outbreak Data Analysis Platform (ODAP) as part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (grant ref MC_PC_20058). This work is supported by the following grants: The PHOSP-COVD study is jointly funded by UK Research and Innovation and National Institute of Health and Care Research (grant references: MR/V027859/1 and COV0319). ISARIC4C is supported by grants from the National Institute for Health and Care Research (award CO-CIN-01) and the Medical Research Council (grant MC_PC_19059) Liverpool Experimental Cancer Medicine Centre provided infrastructure support for this research (grant reference: C18616/A25153). Other grants which have supported this work include: the UK Coronavirus Immunology Consortium [funder reference:1257927], the Imperial Biomedical Research Centre (NIHR Imperial BRC, grant IS-BRC-1215-20013), the Health Protection Research Unit (HPRU) in Respiratory Infections at Imperial College London and NIHR HPRU in Emerging and Zoonotic Infections at University of Liverpool, both in partnership with Public Health England, [NIHR award 200907], Wellcome Trust and Department for International Development [215091/Z/18/Z], Health Data Research UK (HDR UK) [grant code: 2021.0155], Medical Research Council [grant code: MC_UU_12014/12], and NIHR Clinical Research Network for providing infrastructure support for this research. FL is supported by an MRC clinical training fellowship [award MR/W000970/1]. CE is funded by NIHR [grant P91258-4]. LPH is supported by Oxford NIHR Biomedical Research Centre. AART is supported by a BHF Intermediate Clinical Fellowship (FS/18/13/33281). SLRJ receives support from UKRI, GCRF, Rosetrees Trust, BHIVA, EDCTP, Globvac. JDC has grants from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Gilead Sciences, Grifols, Novartis and Insmed. RAE holds a NIHR Clinician Scientist Fellowship (CS-2016-16-020). AH is currently supported by UK Research and Innovation. NIHR and NIHR Manchester BRC. BR receives support from BHF Oxford Centre of Research Excellence, NIHR Oxford BRC and MRC. DGW is supported by an NIHR Advanced Fellowship. AH has received support from MRC and for the Coronavirus Immunology Consortium (MR/V028448/1). LVW has received support from UKRI, GSK/Asthma + Lung UK and NIHR for this study. MGS has received support from NIHR UK, MRC UK and Health Protection Research Unit in Emerging & Zoonotic Infections, University of Liverpool. JKB is supported by the Wellcome Trust (223164/Z/21/Z) and UKRI (MC_PC_20004, MC_PC_19025, MC_PC_1905, MRNO2995X/1, and MC_PC_20029). LT is supported by the Wellcome Trust [clinical career development fellowship grant number 205228/Z/16/Z], the Centre of Excellence in Infectious Diseases Research (CEIDR) and the Alder Hey Charity. PJMO is supported by a NIHR Senior Investigator Award [award 201385]. The funders were not involved in the study design, interpretation of data or writing of this manuscript. The views expressed are those of the authors and not necessarily those of the DHSC, DID, NIHR, MRC, the Wellcome Trust, UK-HAS, the National Health Service, or the Department of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study uses data from the PHOSPCOVID and ISARIC4C study. Written informed consent was obtained from all patients. Ethical approvals for the PHOSPCOVID study were given by Leeds West Research Ethics Committee (20/YH/0225). Ethical approval was given by the South Central-Oxford C Research Ethics Committee in England (reference: 13/SC/0149), Scotland A Research Ethics Committee (20/SS/0028) and World Health Organization Ethics Review Committee (RPC571 and RPC572l; 25 April 2013).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThis is an Open Access article under the CC BY 4.0 license. The PHOSP-COVID protocol, consent form, definition and derivation of clinical characteristics and outcomes, training materials, regulatory documents, information about requests for data access, and other relevant study materials are available online: https://phosp.org/resource/. Access to these materials can be granted by contacting phosp@leicester.ac.uk and Phospcontracts@leicester.ac.uk. The ISARIC4C protocol, data sharing and publication policy are available at https://isaric4c.net. The ISARIC4C Independent Data and Material Access Committee welcomes applications for access to data and materials (https://isaric4c.net). All data used in this study is available within ODAP and accessible under reasonable request. Data access criteria and information about how to request access is available online: https://phosp.org/resource/. If criteria are met and a request is made, access can be gained by signing the eDRIS user agreement. https://phosp.org/resource/